Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Davidson, 2002, Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia, Am J Cardiol, 89, 268, 10.1016/S0002-9149(01)02226-3
Olsson, 2002, Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia, Am Heart J, 144, 1044, 10.1067/mhj.2002.128049
Brown, 2002, Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia, Am Heart J, 144, 1036, 10.1067/mhj.2002.129312
Paoletti, 2001, Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients, J Cardiovasc Risk, 8, 383, 10.1177/174182670100800608
Jones, 1998, Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study), Am J Cardiol, 81, 582, 10.1016/S0002-9149(97)00965-X
Schneck, 2003, Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease, Am J Cardiol, 91, 33, 10.1016/S0002-9149(02)02994-6
NCEP Expert Panel. Third Report of National Cholesterol Education Program (NCER) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final Report. Circulation 2002;106:3143–3421
Wood, 1998, Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention, Eur Heart J, 19, 1434, 10.1053/euhj.1998.1243
Remmell, 1980, Assessing dietary adherence in the Multiple Risk Factor Intervention Trial (MRFIT). I. Use of a dietary monitoring tool, J Am Diet Assoc, 76, 351, 10.1016/S0002-8223(21)05246-9
Myers, 1989, The Centers for Disease Control–National Heart, Lung, and Blood Institute Lipid Standardization Program, Clin Lab Med, 9, 105, 10.1016/S0272-2712(18)30645-0
Warnick, 1978, A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high-density lipoprotein cholesterol, J Lipid Res, 19, 65, 10.1016/S0022-2275(20)41577-9
Friedewald, 1972, Estimation of concentration of low density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499
Lipid Research Clinics Program. Manual of Operations: Lipid and Lipoprotein Analysis. Washington, DC: US Department of Health, Education, and Welfare. Publication no. NIH 75-628, 1982
Miller, 1981
Illingworth, 2001, A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial, Curr Med Res Opin, 17, 43, 10.1185/0300799039117026
Olsson, 2001, Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia, Am J Cardiol, 88, 504, 10.1016/S0002-9149(01)01727-1
Hunninghake, 1998, Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease, J Fam Pract, 47, 349